| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
6-Mercaptopurine monohydrate (6-MP; NSC 755; 6 MP; NSC755; 6MP; NSC-755; Purinethol), the hydrated form of 6-Mercaptopurine, is an approved anticancer and immunosuppressive drug used for the treatment of ALL-acute lymphocytic leukemia, CML-chronic myeloid leukemia, Crohn's disease, and ulcerative colitis. Thiopurine methyltransferase metabolites are incorporated into DNA and RNA, inhibiting de novo purine synthesis.
| Targets |
endogenous purines
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
L6 myotubes are incubated for 24 hours in either DMSO control or 6-Mercaptopurine hydrate (6-MP), with treatments in serum-free DMEM during the last 3 hours. They are then incubated for an additional 60 minutes at 37°C in the presence or absence of 100 nM insulin. Subsequently, 50 μg of protein lysates are gathered, put through SDS-PAGE, and then immunoblotted using primary antibodies for an entire night at 4°C. Using Image J software, densitometric analysis of scanned films is used to finally quantify the proteins[2].
|
|
| Cell Assay |
The Cell Viability Assay is used to quantify cell viability. 10,000 L6 skeletal muscle cells are seeded per well in 96-well plates, and after 7 days, the cells differentiate into myotubes. Before the assay, cells are treated for 24 hours with varying doses of 6-Mercaptopurine hydrate (6-MP). After 30 minutes of room temperature equilibration, 50 μL of Cell Titer-Glo reagent is added to each well, and the plates are mixed for 12 minutes on an orbital shaker to analyze the viability of the cells. A luminometer is used to measure luminosity[2].
|
|
| Animal Protocol |
|
|
| References |
|
| Molecular Formula |
C5H6N4OS
|
|
|---|---|---|
| Molecular Weight |
170.19
|
|
| Exact Mass |
170.03
|
|
| Elemental Analysis |
C, 35.29; H, 3.55; N, 32.92; O, 9.40; S, 18.84
|
|
| CAS # |
6112-76-1
|
|
| Related CAS # |
50-44-2
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1=NC2=C(N1)C(=S)N=CN2.O
|
|
| InChi Key |
WFFQYWAAEWLHJC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2
|
|
| Chemical Name |
3,7-dihydropurine-6-thione;hydrate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8758 mL | 29.3789 mL | 58.7579 mL | |
| 5 mM | 1.1752 mL | 5.8758 mL | 11.7516 mL | |
| 10 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05506332 | Recruiting | Drug: 6-mercaptopurine Drug: Venetoclax |
Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory |
University Hospital, Antwerp | July 15, 2022 | Phase 1 |
| NCT05276284 | Recruiting | Combination Product: Atezolizumab, 6-mercaptopurine, 6-thioguanine |
Solid Tumor, Adult Metastatic Cancer |
Kristoffer Rohrberg | September 1, 2022 | Phase 1 Phase 2 |
| NCT01432145 | Completed | Drug: 6-Mercaptopurine Drug: Methotrexate |
Breast Cancer Ovarian Cancer |
University of Oxford | May 2011 | Phase 2 |
| NCT01324336 | Completed | Drug: 6-Mercaptopurine | Acute Lymphoblastic Leukemia | Children's Mercy Hospital Kansas City |
July 2011 | N/A |
| NCT00548431 | Completed | Drug: 6-mercaptopurine | Leukemia, Lymphocytic, Acute | Rigshospitalet, Denmark | December 2007 | Phase 2 |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
